Adult Solid Tumor Clinical Trial
Official title:
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
This will be a randomized blinded clinical trial. Patients will be randomized to receive either a remifentanil or dexmedetomidine infusion for general anesthesia. The anesthesia team will know the result of randomization at induction. Data will be gathered by research personnel who will be blinded to the anesthetic method used. Patients will be blinded to the anesthetic they receive till they are discharged from the PACU when they will have the option to be unblinded. The Data Safety and -Toxicity Committee will review all serious adverse events and toxicity reports as well as annual reviews.
Anesthesia for craniotomy presents a unique challenge to the anesthesiologist. Anesthesia for neurosurgical procedures should provide optimal surgical conditions while maintaining appropriate cerebral oxygen supply and stable systemic hemodynamics. (1) It is important to prevent patient response to noxious stimuli during the procedure like pinning, drilling of the bone, opening and manipulation of the dura etc., avoid coughing and bucking during surgery and during extubation thus necessitating a deeper level of anesthesia and analgesia. At the same time it is desirable to have the patient fully awake toward the end of the surgery in order to facilitate neurologic evaluation. Management of the above presents a challenge during induction, maintenance and extubation and also during multiple critical stages of surgery Fear of the side effects of analgesic drugs frequently leads to the under-treatment of post-craniotomy pain. (2) Nevertheless, this pain continues to be commonly observed, is frequently severe, and, if unrelieved, may cause distress for the neurosurgical patient and serious complications for the operative brain. (2) There is a need for larger trials to delineate safety and efficacy of analgesic therapies with a focus on short- and long-term outcomes. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04538625 -
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
|
Phase 3 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Recruiting |
NCT06403436 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03061305 -
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
|
||
Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
Terminated |
NCT05357898 -
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06277804 -
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
|
Phase 1 | |
Completed |
NCT03818347 -
Hydrogen Gas for Cancer Rehabilitation
|
N/A | |
Completed |
NCT05400265 -
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04705818 -
Combining Epigenetic And Immune Therapy to Beat Cancer.
|
Phase 2 | |
Suspended |
NCT03253575 -
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
|
||
Completed |
NCT04084951 -
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03760952 -
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
|
||
Active, not recruiting |
NCT03445858 -
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
|
Early Phase 1 | |
Completed |
NCT03303365 -
Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence
|
N/A | |
Not yet recruiting |
NCT05666635 -
Study of LTC004 in Subjects With Advanced Malignant Tumors
|
Phase 1 | |
Recruiting |
NCT05752552 -
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
|
Phase 1 | |
Active, not recruiting |
NCT05147272 -
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT04892043 -
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
|
Phase 1 |